In the past few decades, advancements in protein engineering, biotechnology, and structural biochemistry have resulted in the discovery of various techniques that enhanced the production yield of ...

Shreehas Tambe, CEO & Managing Director, Biocon Biologics Ltd., said, “The approval of YESAFILI by Health Canada—the first biosimilar to EYLEA in Canada—is a proud moment for Biocon Biologics.

Biocon Biologics secures Health Canada approval for Yesafili, the first biosimilar to Eylea® in Canada, with a global launch scheduled for July 4, 2025, targeting treatment of serious eye diseases.

Bayer AG (Germany) Bayer AG plays a key role in the ophthalmology drugs market by marketing Eylea and investing in advanced therapies such as cell and gene therapy.

Biocon Biologics receives Health Canada approval for its biosimilar Yesafili injection, used to treat various eye ailments. Launch is scheduled for July 4, 2025.

Biocon Biologics Ltd. (BBL), announced that Health Canada has granted a Notice of Compliance (NOC) for Yesafili (aflibercept), a biosimilar to Eylea injection, in vial and prefilled syringe ...

Bayer AG rose nearly 2 percent as it secured the European Commission's approval for the eight-milligram dose of its Eylea drug. Sportswear makers Puma and Adidas surged 4-5 percent after U.S. peer ...

Plus more pharma news from the Pharmalot campus, brought to you by the Pharmalittle newsletter.

Shreehas Tambe, CEO & Managing Director, Biocon Biologics Ltd., said: "The approval of YESAFILI by Health Canada-the first biosimilar to EYLEA® in Canada-is a proud moment for Biocon Biologics. We are ...

Shreehas Tambe, CEO & Managing Director, Biocon Biologics Ltd., said: “The approval of YESAFILI by Health Canada—the first biosimilar to EYLEA® in Canada—is a proud moment for Biocon Biologics.

Indian drugmaker Biocon has announced that Health Canada has granted a Notice of Compliance for Yesafili (aflibercept), a biosimilar to Eylea (aflibercept) injection, in vial and prefilled syringe ...